|Bid||109.69 x 800|
|Ask||110.11 x 1100|
|Day's range||109.20 - 111.63|
|52-week range||55.90 - 114.33|
|Beta (5Y monthly)||0.50|
|PE ratio (TTM)||N/A|
|Earnings date||05 Nov 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||116.00|
Oncology firm Guardant Health bounced off its 10-week moving average after a breakout from a base in September.
Many cancer patients undergoing treatment have impaired immune systems, so it's not a big surprise that some of them stayed away from clinic settings during the spring, when cases of COVID-19 were growing rapidly in the United States. Guardant Health (NASDAQ: GH), a company specializing in detecting cancer DNA circulating in the blood, saw a dip in clinical volume during that time, dampening results after the company more than doubled its revenue last year. Guardant's revenue comes from tests taken by seriously ill cancer patients and drug companies conducting research in new treatments, and neither of those sorts of customers are going to put off buying the company's products for long.
Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the third quarter 2020 after market close on Thursday, November 5, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.